AffiliationInstitute of Cancer Studies, Christie Hospital and University of Manchester, Wilmslow Road, Withington, Manchester, UK.Gordon.Jayson@Manchester.ac.ukCenter for Cancer Research, National Cancer Institute, Bethesda MD, USAInstitute of Cancer Studies, St Marys Hospital and University of Manchester, Manchester, UKUCL Cancer Institute, University College London, London, UK
MetadataShow full item record
AbstractEpithelial ovarian cancer is the commonest cause of gynaecological cancer-associated death. The disease typically presents in postmenopausal women, with a few months of abdominal pain and distension. Most women have advanced disease (International Federation of Gynecology and Obstetrics [FIGO] stage III), for which the standard of care remains surgery and platinum-based cytotoxic chemotherapy. Although this treatment can be curative for most patients with early stage disease, most women with advanced disease will develop many episodes of recurrent disease with progressively shorter disease-free intervals. These episodes culminate in chemoresistance and ultimately bowel obstruction, the most frequent cause of death. For women whose disease continues to respond to platinum-based drugs, the disease can often be controlled for 5 years or more. Targeted treatments such as antiangiogenic drugs or poly (ADP-ribose) polymerase inhibitors offer potential for improved survival. The efficacy of screening, designed to detect the disease at an earlier and curable stage remains unproven, with key results expected in 2015.
CitationOvarian cancer. 2014: Lancet
- Management and Treatment of Recurrent Epithelial Ovarian Cancer.
- Authors: Armbruster S, Coleman RL, Rauh-Hain JA
- Issue date: 2018 Dec
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
- Authors: Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P
- Issue date: 2018 Dec 27
- Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
- Authors: Rafii S, Gourley C, Kumar R, Geuna E, Ern Ang J, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA
- Issue date: 2017 Jul 18
- Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.
- Authors: Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD 2nd, Abkevich V, Potter J, Pruss D, Glenn P, Li Y, Li J, Gonzalez-Angulo AM, McCune KS, Markman M, Broaddus RR, Lanchbury JS, Lu KH, Mills GB
- Issue date: 2010 Aug 1
- Recent progress in the diagnosis and treatment of ovarian cancer.
- Authors: Jelovac D, Armstrong DK
- Issue date: 2011 May-Jun